As an antiangiogenic agent, ginsenoside Rg3 reduces VEGF expressions in cancer cells and attenuates the phosphorylation cascade of the VEGF-dependent p38/ERK signaling in vitro, which has also been confirmed in leukemia [12, 34, 35]. The gene discussed is VEGFA; the disease is cancer.